Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell takes Proactive's Stephen Gunnion through the company's interim results and key highlights across the company's diabetes and obesity programs. Howell emphasised advancements in its proprietary pipeline, including significant clinical data on AT278, an ultra-concentrated, ultra-rapid-acting insulin shown to be superior in patients with Type 1 and Type 2 diabetes. She also discussed their progress with a new oral GLP-1 formulation in collaboration with TRx Biosciences and the promising future studies planned for 2025. The conversation also highlighted Arecor's strategic partnership with Medtronic to develop a stable, long-wear insulin for implantable pumps, aimed at a vulnerable patient group requiring advanced insulin therapies. Howell noted the importance of licensing deals, like AT220, which are driving revenue through royalties and validating their Arestat technology. The company's partnerships with major pharmaceutical firms like Eli Lilly, Sanofi, and Medtronic continue to be critical to its success. In closing, Howell expressed confidence in Arecor’s strategy and highlighted its potential for creating long-term value. She also provided updates on the specialty pharmaceutical business Tetris Pharma, particularly their glucagon pen Ogluo®, for severe hypoglycemia, which is showing market growth in the UK and Germany. Stay tuned for more updates from Arecor Therapeutics and don't forget to like the video, subscribe to Proactive's channel, and enable notifications for the latest interviews and insights. #ArecorTherapeutics #DiabetesResearch #ObesityTreatment #InsulinPump #PharmaPartnerships #GLP1 #Medtronic #TetrisPharma #Biotech #HealthcareInnovations #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews